Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)244.85m
- Net income in SEK-323.94m
- Incorporated1997
- Employees124.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hamlet BioPharma AB | 0.00 | -57.59m | 805.66m | 7.00 | -- | 27.98 | -- | -- | -0.3183 | -0.3183 | 0.00 | 0.2091 | 0.00 | -- | -- | 0.00 | -97.85 | -78.53 | -109.76 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Medivir AB | 8.50m | -94.40m | 864.03m | 10.00 | -- | 2.72 | -- | 101.65 | -0.6372 | -0.6372 | 0.0596 | 0.5895 | 0.0355 | -- | 1.97 | 850,000.00 | -39.42 | -35.87 | -47.59 | -42.96 | -- | -- | -1,110.59 | -925.95 | -- | -51.44 | -- | -- | 143.97 | -9.43 | 23.45 | -- | -- | -- |
| Nykode Therapeutics ASA | 0.00 | -110.23m | 892.42m | 59.00 | -- | 1.08 | -- | -- | -0.3556 | -0.3556 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -9.66 | -13.65 | -10.28 | -15.31 | -- | -- | -- | -220.65 | -- | -- | 0.0271 | -- | -100.00 | -- | 68.47 | -- | -17.43 | -- |
| Curasight A/S | -63.79m | -68.89m | 1.07bn | 4.00 | -- | 42.79 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -171.45m | 1.09bn | 26.00 | -- | 1.81 | -- | -- | -4.44 | -4.44 | 0.00 | 14.49 | 0.00 | -- | -- | 0.00 | -21.90 | -25.02 | -24.53 | -27.10 | -- | -- | -- | -- | 7.41 | -10.72 | 0.1971 | -- | -- | -- | 39.95 | -- | -20.78 | -- |
| Cantargia AB | 316.70m | 146.98m | 1.18bn | 22.00 | 8.01 | 4.43 | 7.83 | 3.72 | 0.5912 | 0.5912 | 1.27 | 1.07 | 1.36 | -- | 4.89 | 14,395,550.00 | 62.93 | -49.66 | 76.73 | -57.73 | -- | -- | 46.41 | -326.18 | -- | 21.62 | -- | -- | -- | -- | 190.92 | -- | -44.55 | -- |
| Nightingale Health Oyj | 50.06m | -196.93m | 1.35bn | 100.00 | -- | 1.41 | -- | 26.93 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Thor Medical ASA | 94.93k | -55.92m | 1.43bn | 13.00 | -- | 3.14 | -- | 15,065.97 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| Solar Foods Oyj | 203.86k | -113.77m | 1.50bn | 57.00 | -- | 6.61 | -- | 7,349.74 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Devyser Diagnostics AB | 250.60m | -8.40m | 1.50bn | 116.00 | -- | 4.24 | 83.92 | 5.99 | -0.5142 | -0.5142 | 15.09 | 21.27 | 0.5312 | 1.45 | 4.65 | 2,160,345.00 | -1.95 | -8.59 | -2.30 | -9.76 | 80.61 | 81.08 | -3.67 | -22.20 | 2.36 | 0.6429 | 0.1278 | -- | 15.49 | 30.70 | 86.34 | -- | 83.06 | -- |
| BioInvent International AB | 244.85m | -323.94m | 1.53bn | 124.00 | -- | 2.24 | -- | 6.25 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Intellego Technologies AB | 737.96m | 191.84m | 1.55bn | 64.00 | 7.01 | 11.41 | 7.22 | 2.10 | 6.64 | 6.64 | 23.96 | 4.08 | 2.03 | 11.02 | 15.11 | 11,530,660.00 | 52.66 | -15.74 | 75.55 | -23.48 | 60.32 | 13.73 | 26.00 | -33.49 | 2.53 | 3.94 | 0.0642 | -- | 4.34 | 67.41 | -70,300.74 | -- | 36.08 | -- |
| Egetis Therapeutics AB (publ) | 62.50m | -342.60m | 1.81bn | 40.00 | -- | 5.36 | -- | 29.02 | -0.9237 | -0.9237 | 0.1698 | 0.8571 | 0.0873 | 30.36 | 3.60 | 1,562,500.00 | -47.87 | -39.01 | -69.47 | -46.68 | 19.84 | 61.77 | -548.16 | -577.70 | 1.04 | -35.79 | 0.1951 | -- | 35.36 | 8.94 | 0.3201 | -- | 128.65 | -- |
| Cereno Scientific AB | 0.00 | -113.30m | 1.97bn | 5.00 | -- | 9.63 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Diamyd Medical AB | 348.00k | -182.46m | 1.99bn | 41.00 | -- | 8.81 | -- | 5,714.11 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
Data as of Mar 02 2026. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
34.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2024 | 10.02m | 15.23% |
| HBM Partners AG (Investment Management)as of 31 Dec 2024 | 5.08m | 7.71% |
| Fj�rde AP-fondenas of 31 Dec 2024 | 4.02m | 6.11% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 1.32m | 2.00% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Nov 2025 | 742.90k | 1.13% |
| Atle Fund Management ABas of 31 Dec 2024 | 475.75k | 0.72% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2025 | 450.00k | 0.68% |
| SEB Funds ABas of 30 Jan 2026 | 397.89k | 0.61% |
| Skandia Investment Management ABas of 28 Nov 2025 | 288.79k | 0.44% |
| Storebrand Asset Management ASas of 31 Jan 2026 | 136.04k | 0.21% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
